Migraine reduction by intravenous and oral magnesium
Migraine headache can cause intense throbbing or a pulsing sensation in one area of the head and is commonly accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Migraine attacks can cause significant and severe pain for hours to days and they have been associated with magnesium deficiency. Previous studies investigated the effect of intravenous and oral magnesium on acute migraine attacks and the prevention of migraine have produced equivocal findings.
To evaluate the effects of intravenous magnesium on acute migraine attacks and oral magnesium supplements on migraine prophylaxis, a meta-analysis of randomized controlled trials was conducted.
This review was conducted according to the guidelines of the PRISMA. Only RCTs which evaluated the effects of intravenous or oral magnesium on migraine compared with a group were included.
A total of 21 studies were included in the randomized controlled trial. Among that, 11 studies investigated the effects of intravenous magnesium on acute migraine (948 participants) and 10 examined the effects of oral magnesium on migraine prophylaxis (789 patients). However, intravenous magnesium significantly relieved acute migraine within 15-45 minutes, 120 minutes and 24 hours after the initial infusion (odd ratios = 0.23, 0.20 and 0.25 respectively). Oral magnesium significantly alleviated the frequency and intensity of migraine.
After analysis, intravenous magnesium reduces acute migraine attacks within 15-45 minutes, 120 minutes and 24 hours after the initial infusion and oral magnesium alleviates the frequency and intensity of migraine. It has been concluded that intravenous and oral magnesium should be adapted as parts of multi modal approach to reduce the migraine.